• Amikacin Sulfate: From MIC to Model Design

  2026-09-16

  Amikacin Sulfate is a powerful benchmark for designing intracellular and non-tuberculous mycobacterial infection assays. This guide connects mechanism, concentration interpretation, delivery biology, and KR-12 peptide research to improve experimental decisions.

• Amikacin Sulfate for Granuloma-Targeted Research

  2026-09-16

  Amikacin Sulfate supports a practical progression from MIC and CFU testing to intracellular uptake and granuloma-localized delivery. This guide translates dendritic-cell targeting research into assay design, workflow controls, and troubleshooting decisions for non-tuberculous mycobacterial studies.

• Neomycin Sulfate as a Translational Mechanism Probe

  2026-09-15

  Neomycin sulfate is more than an aminoglycoside antibiotic: it is a versatile mechanistic probe for RNA/DNA structure interaction studies, ribozyme catalysis, viral RNA recognition, DNA triplex stabilization, and ion-channel function. This thought-leadership perspective shows how to deploy its distinct activities without overextending evidence from microbiome and inflammatory disease models.

• Everolimus (RAD001): mTOR Research Guide

  2026-09-15

  Everolimus, also called RAD001, is an orally bioavailable mTOR pathway inhibitor that forms an FKBP12 complex and suppresses mTOR signaling. Its benchmark antiproliferative values require careful interpretation because in vitro growth inhibition does not equal cell killing.

• ARCA Cy5 EGFP mRNA (5-moUTP): Assay Guide

  2026-09-14

  Learn how ARCA Cy5 EGFP mRNA (5-moUTP), SKU R1009, can separate delivery, localization, and translation variables in mammalian-cell viability and cytotoxicity workflows. This scenario-based guide covers assay design, handling, interpretation, and practical vendor selection.

• DiscoveryProbe FDA-Approved Drug Library for HDT

  2026-09-14

  Learn how the DiscoveryProbe FDA-approved Drug Library can support host-directed infection research through phenotype-first screening, orthogonal validation, and mechanism-aware assay design. A loperamide study provides a practical framework for drug repositioning screening with clinically annotated compounds.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia Models

  2026-09-13

  This study combines genetic ablation, inducible mouse models, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related chondrodysplasia. NVP-BGJ398 partially improved chondrocyte behavior and skeletal architecture, supporting FGFR3 pathway inhibition as a research direction while leaving important questions about dose, disease severity, and human translation.

• NVP-BGJ398 Phosphate: FGFR Translation

  2026-09-12

  NVP-BGJ398 phosphate offers a biomarker-led framework for studying FGFR1/2/3 signaling across cancer and skeletal disease models. This thought-leadership article connects molecular selectivity, pharmacodynamic validation, formulation strategy, and translational decision-making.

• Alternariol: A Decision Framework for Toxicology

  2026-09-11

  Alternariol (AOH) is more than a foodborne mycotoxin: it is a mechanistically rich probe for studying hepatic stellate-cell activation, apoptosis, and cytochrome P450 biology. This evidence-based guide shows how to choose models, endpoints, controls, and orthogonal assays without overinterpreting cell-specific findings.

• CAY10499: HSL and MGL Inhibitor for Lipid Research

  2026-09-11

  CAY10499 is an inhibitor of human hormone sensitive lipase with additional activity against monoglyceride lipase and FAAH. Its biochemical profile supports controlled lipid-hydrolysis assays, but it should not be treated as an ACLY inhibitor, cannabinoid-receptor antagonist, diagnostic reagent, or therapeutic agent.

• Biotin-tyramide for Spatial Senescence Assays

  2026-09-10

  Biotin-tyramide combines HRP-driven spatial deposition with flexible fluorescence or chromogenic detection, making it useful for low-abundance RNA, chromatin, and protein targets in senescence studies. This guide translates findings on PURPL and H3K9me3 into practical IHC and ISH workflows, with executable starting conditions and troubleshooting strategies.

• Biomimetic Chromatography for Pulmonary Permeability

  2026-09-10

  This study provides a direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for modelling drug–membrane partitioning and pulmonary permeability. Its findings position LEKC as the more physiologically informative approach for many compounds, while IAM LC remains attractive for broad, robust, and high-throughput screening.

• STING, CD40, and TLS in ESCC B-Cell Activation

  2026-09-09

  A recent ESCC study links tertiary lymphoid structures with favorable survival and identifies IRF4-positive B-cell activation as a central immune feature. Its mechanistic contribution is the demonstration that CD40 and STING compete for TRAF2, connecting non-canonical NF-κB signaling with TLS-associated antitumor immunity.

• REV1–DHX36 Control of G-Quadruplex Replication

  2026-09-09

  A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The work defines a two-tier mechanism for G4 tolerance and clarifies how REV1 deficiency alters mutagenesis, replication dynamics, and ATM/ATR DNA damage signaling.

• Moxifloxacin Research Workflows and Applications

  2026-09-08

  Moxifloxacin supports complementary bacterial gyrase, mammalian cytotoxicity, and preclinical metabolic-response studies. This guide translates its chemical properties and dose-dependent biology into practical assay workflows, controls, and troubleshooting decisions.

8587 records 1/573 page Next 12345 下5页 Last page